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ospedaleuniverona.itAbstractObjective: Chromosomal rearrangements of the RET proto-oncogene is one of the most common molecular events in
papillary thyroid carcinoma (PTC). However, their pathogenic role and clinical significance are still debated. This study aimed
to investigate the prevalence of RET/PTC rearrangement in a cohort of BRAF WT PTCs by fluorescence in situ hybridization
(FISH) and to search a reliable cut-off level in order to distinguish clonal or non-clonal RET changes.
Design: Forty BRAF WT PTCs were analyzed by FISH for RET rearrangements. As controls, six BRAFV600E mutated PTCs,
13 follicular adenomas (FA), and ten normal thyroid parenchyma were also analyzed.
Methods: We performed FISH analysis on formalin-fixed, paraffin-embedded tissue using a commercially available RET
break–apart probe. A cut-off level equivalent to 10.2% of aberrant cells was accepted as significant. To validate FISH results,
we analyzed the study cohort by qRT-PCR.
Results: Split RETsignals above the cut-off level were observed in 25% (10/40) of PTCs, harboring a percentage of positive cells
ranging from 12 to 50%, and in one spontaneous FA (1/13, 7.7%). Overall, the data obtained by FISH matched well with qRT-
PCR results. Challenging findings were observed in five cases showing a frequency of rearrangement very close to the cut-off.
Conclusions: FISH approach represents a powerful tool to estimate the ratio between broken and non-broken RET tumor
cells. Establishing a precise FISH cut-off may be useful in the interpretation of the presence of RET rearrangement, primarily
when this strategy is used for cytological evaluation or for targeted therapy.European Journal of
Endocrinology
(2015) 172, 571–582IntroductionPapillary thyroid carcinoma (PTC) is the most prevalent
form of thyroid cancers, accounting for 80% of all cases.
It is characterized by genetic alterations leading to the
activation of the MAPK signaling pathway. Together with
BRAF point mutations, RET gene rearrangements represent
the two most common molecular events in PTC (1, 2, 3).The rearranged during transfection (RET) proto-
oncogene maps to the long arm of chromosome 10 at
band q11.2 and encodes for a transmembrane tyrosine-
kinase receptor involved in the control of cell diffe-
rentiation, cell proliferation, and cell survival (4, 5).
Oncogenic activation of the RET gene via chromosomal
AUTHOR COPY ONLY
250 PTC tumor samples
210 PTC BRAF V600E (84%)
204 PTC
RET ND
10 PTC RET rearranged
(25%)
Control group13 FA
RET tested
10 NTP
RET tested
6 PTC
RET tested
40 PTC BRAF WT (16%)
Figure 1
Schematic representation of the study design. ND, not
determined.
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172 :5 572rearrangement is generally related to radiation exposure
and young age (40–70%), but may be found in non-
radiated thyroid tumors and in adults (20–40%) (6, 7).
Moreover, a recent study has revealed that 18% of
poorly differentiated thyroid carcinomas (PDTC) and 9%
of radioactive iodine (RAI) refractory-FDG-PET-positive
PDTC harbored RET/PTC rearrangements (8).
These rearrangements (balanced inversions or trans-
locations) derive from the fusion of the 3 0 portion of the
RET gene to the 5 0 portion of several heterologous genes
and create fusion proteins with transforming activity, as
demonstrated in in vitro experiments and in transgenic
mice models (9, 10, 11, 12).
To date, at least 13 different forms of RET rearrange-
ment have been documented (13), with RET/PTC1
(consisting of the fusion of RET with the H4 gene) and
RET/PTC3 (consisting of the fusion of RET with the
RFG/ELE1 gene) being the most common (2, 14).
A wide range of prevalence of RET/PTC rearrange-
ments in human PTC has been reported, ranging from 3%
in Saudi Arabia, 29–35% in Italy, 40% in Canada, to 85%
in Australia (15, 16, 17, 18), which can be attributed to
ethnical and geographic variability as well as to different
sensitivities of detection methods, tumor heterogeneity,
age, and radiation exposure (6, 19, 20, 21, 22, 23, 24,
25, 26, 27, 28, 29, 30, 31). Indeed, non-clonal RET/PTC
rearrangements have been found not only in PTC but also
in 10–45% of follicular thyroid adenomas, oncocytic
thyroid tumors, and Hashimoto’s thyroiditis (30, 32, 33,
34, 35, 36, 37, 38, 39).
The specificity of this rearrangement, as a marker of
PTC, has been challenged, and its clinical significance is
still under debate. Thus, finding a reliable and biologically
relevant strategy for RET/PTC detection may have import-
ant clinical and diagnostic implications as the detection of
RET/PTC has been offered as a diagnostic tool for PTC in
the surgical and preoperative cytological material (40, 41,
42, 43, 44, 45). Moreover, the emergence of drugs that
selectively inhibit RET kinase activity highlights the need
of a better understanding of RET/PTC distribution within
the tumor volume and of standardization of the detection
methods for this rearrangement (46, 47, 48, 49). Inter-
phase fluorescence in situ hybridization (FISH) represents
the gold standard method for detecting gene rearrange-
ments at the single-cell level and is the most sensitive
mean for identifying and quantifying intratumoral gen-
etic heterogeneity (50, 51, 52).
The aim of this study was to test a new commercially
available RET break–apart probe on formalin-fixed,
paraffin-embedded (FFPE) samples, to investigate thewww.eje-online.orgprevalence of RET/PTC in a cohort of BRAF WT PTCs, to
search for a reliable cut-off level in an attempt to
distinguish the clonal or non-clonal event of the RET
rearrangements, and to explore whether RET/PTC may be
a relevant pathogenic factor.Materials and methods
Samples collection
Forty cases of BRAFWT PTC (31 sporadic; two familial, one
familial adenomatous polyposis-associated PTC and six
with history of exposure to external beam radiotherapy)
were analyzed during the study.
The cases were selected from a consecutive series of
250 PTCs collected from 2003 to 2013 from the files of
the Pathology Unit, University of Verona. Previously, all
samples had been tested for BRAFV600E mutation status
(Fig. 1). The histology of all tumor samples was confirmed
independently by two pathologists (C C and M B) and
classified according to the World Health Organization
guidelines (53). As a control group, six BRAFV600E
mutated PTCs and 13 follicular adenomas (FA) (12 sporadic
and one with a history of exposure to external beam
radiotherapy) were also tested for RET rearrangements
(Fig. 1). BRAF WT tumor tissue samples were obtained
from 37 patients; in three patients with multifocal disease
we examined two neoplastic foci (Table 1, cases 2a and 2b,
17a and 17b, 20a and 20b). Moreover, one case of
BRAFV600E mutated PTCs (Table 1, case 18b) belonged
AUTHOR COPY ONLY
Table 1 Clinico-pathological and molecular findings in PTC.
Samples
Age
(years) Gender
Radiation
exposure
Diameter
(mm) Histological variant Thyroiditis Stage
Split RET
signals
(%)
RET/PTC
rearrange-
ment
BRAF-
V600E
status
Follow-
up
1 49 F No 4 Oncocytic No I 2 Negative WT NED
2a 15 F No 12 Classical Yes I 2 Negative WT BPD
2b 15 F No 5 Classical Yes I 0 Negative WT BPD
3 26 F No 16 Follicular Yes I 6 Negative WT NED
4 44 F No 15 Follicular No I 4 Negative WT NED
5 36 F No 24 Follicular No I 4 Negative WT NED
6 27 F No 10 Follicular Yes I 6 RET/PTC1 WT NED
7 19 M No 40 Follicular No I 3 Negative WT NED
8 29 F No 40 Tall Cell Yes I 4 Negative WT BPD
9 35 F No 20 Cribriform morular Yes I 6 Negative WT NED
10 20 F No 35 Follicular No I 2 Negative WT NED
11 34 F No 8 Classical Yes I 2 Negative WT NED
12 18 F No 8 Classical No I 9 RET/PTC3 WT NED
13 37 F No 10 Follicular Yes I 4 Negative WT NED
14 36 F No 38 Follicular No I 2 Negative WT NED
15 24 M No 45 Follicular No I 10 Negative WT BPD
16 29 F No 20 Follicular Yes I 10 RET/PTC1 WT NED
17a 55 F No 9 Follicular Yes II 6 Negative WT NED
17b 55 F No 22 Follicular Yes II 8 Negative WT NED
18a 43 F No 10 Cribriform morular Yes III 4 Negative WT NED
19 65 M No 45 Follicular No III 10 Negative WT NED
20a 53 F No 14 Follicular Yes III 8 Negative WT BPD
21 69 F No 48 Solid No III 0 Negative WT PD
22 57 M No 55 Solid No IVa 4 Negative WT BPD
23 75 F No 60 Classical withminor
poorly differen-
tiated com-
ponent
No IVc 5 Negative WT Dead
24 36 M No 35 Follicular No I 48 RET/PTC1 WT SpeD
25 11 F No 45 Solid No I 50 RET/PTC3 WT SpeD
26 37 F No 11 Solid Yes I 13 RET/PTC1 WT BPD
27 27 F No 11 Classical Yes I 28 RET/PTC1 WT NED
28 39 F No 25 Classical No I 20 RET/PTC1 WT SpeD
29 34 F No 17 Diffuse sclerosing Yes I 26 RET/PTC1 WT NED
30 36 F No 50 Follicular Yes I 50 RET/PTC1 WT NED
31 11 F No 20 Diffuse sclerosing Yes I 18 RET/PTC1 WT Lost at
follow
up
20b 53 F No 20 Follicular Yes III 12 RET/PTC1 WT BPD
32 26 M Yes 22 Classical No I 30 RET/PTC1 WT SpeD
33 38 M Yes 8 Follicular No I 0 Negative WT NED
34 8 F Yes 6 Classical No I 4 Negative WT BPD
35 29 F Yes 9 Classical No I 1 Negative WT NED
36 36 M Yes 3 Classical No I 0 Negative WT Dead of
other
disease
37 49 M Yes 7 Classical No I 2 Negative WT NED
1 40 F No 16 Classical No I 4 Negative V600E NED
2 30 M No 20 Classical Yes I 2 Negative V600E NED
3 32 F No 6 Classical No I 8 Negative V600E BPD
4 29 F No 7 Classical No I 6 Negative V600E NED
5 53 F No 7 Classical No I 6 Negative V600E NED
18b 43 F No 8 Follicular Yes III 5 Negative V600E NED
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172 :5 573to a patient included in the BRAFV600E WT group
(Table 1, case 18a). Concerning the cases exposed to
external irradiation (six PTC and one FA), the patients
received radiation therapy for primary cancer (onethymoma, one brainstem glioma, three leukemias, one
cerebellar astrocytoma, one rhabdomyosarcoma of the
neck), during childhood (four patients) or as adults (three
patients). The radiation dose was available only for onewww.eje-online.org
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172 :5 574patient and amounted to 18 Gy (Table 1, case 35).
Regarding the PTC subset, the tumor latency was as
follows: 7, 3, 6, 25, 16, and 45 years respectively
(Table 1, cases 32–37); for the FA, the latency was 25
years (Table 2, case 1).
The medical records of each patient (42 with PTC: 37
WT, and five BRAF-mutated and 13 with FA) were reviewed
to obtain clinical and demographic data. Informed
consent was obtained from all patients, as per the
recommendations of our Ethics Committee.Fluorescence in situ hybridization
To evaluate RET/PTC rearrangements (either inversion
10q11.2 or translocations), FISH was performed using the
REPEAT-FREE POSEIDON RET (10q11) break–apart probe
(Kreatech Diagnostics, Amsterdam, The Netherlands) on
FFPE samples.
This commercial probe is designed as a dual-color
probe where the two regions across the break-point, the
proximal and the distal region to RET (10q11), are direct-
labeled with Platinum Bright 550 and with Platinum
Bright 495 respectively.
The FISH procedure was performed following Krea-
tech’s protocol with modifications designed in our
laboratory, in particular regarding the tissue digestion
and the hybridization times (54).
In brief, 3 mm thick FFPE tissue sections were mounted
on positively charged slides and air dried. Targeted tumor
areas were circled with a pen, after review of theTable 2 Clinicopathological and molecular findings in follicular a
Samples
Age
(years) Gender
Radiation
exposure
Diameter
(mm)
Histo
type
1 35 M Yes 6 Follic
2 52 M No 22 Follic
3 32 F No 27 Follic
4 54 F No 25 Follic
5 31 F No 40 Follic
6 46 F No 35 Onco
7 39 F No 25 Onco
8 54 F No 30 Onco
9 54 F No 6 Onco
10 60 M No 40 Onco
11 51 M No 11 Onco
12 56 M No 20 Onco
13 51 F No 8 Hyali
tra
NED, not evidence of disease; SPeD, structural persistence disease; BPD, bioche
2a and 2b, 17a and 17b, 18a and 18b, 20a and 20b: each paired sample derived
www.eje-online.orgcorresponding hematoxylin and eosin (H&E) stained
slide by a pathologist.
The sections were deparaffinized with two 10-min
washes in xylene, hydrated in 100, 85, and 70% ethanol
solutions for 10 min each, rinsed in distilled water for
10 min, fixed in methanol:acetic acid 3:1 for 10 min and
air-dried. Next, the sections were treated in a 2! SSC
solution for 15 min at 37 8C, and then dehydrated in
consecutive 70, 85, and 100% ethanol solutions for 1 min
each, then dried. The sections were then bathed in 0.1 mM
citrate buffer (pH 6) solution at 85 8C for 30 min and again
dehydrated in a series of ethanol solutions and dried.
The slides were incubated in 0.75 ml of pepsin (Sigma)
solution (4 mg/ml in 0.9% NaCl, pH 1.5) for 15 min at
37 8C, washed again, dehydrated again in graded ethanol
solutions (70, 85, and 100%) for 2 min each and dried.
A total of 10 ml RET (10q11) break–apart probe was
placed on the designated hybridization area and sealed
with rubber cement.
A ThermoBrite denaturation-hybridization system
(Abbott Molecular) set at 80 8C was used for codenatura-
tion of probe and target DNA for 10 min, before
hybridization at 37 8C overnight.
The rubber cement and coverslip were removed and
the slides were placed in 0.3% NP-40/2! SSC solution at
first for 15 min at room temperature and then at 72 8C for
2 min. The sections were then rinsed in H2O for 1 min, air-
dried, and counterstained with 10 ml of DAPI/Antifade
(ProLong Gold Antifade Reagent with DAPI; Life Technol-
ogies). The slides were examined using an Olympus BIX-61denoma.
logical
Architectural pattern
Split RET
signals (%)
ular Normo-macrofollicular 2
ular Microfollicular and trabecular 4
ular Microfollocular and trabecular 12
ular Normo-macrofollicular 3
ular Microfollicular 4
cytic Solid and follicular 2
cytic Microfollicular and trabecular 1
cytic Normo-macrofollicular 6
cytic Microfollicular and trabecular 2
cytic Solid-trabecular 1
cytic Normo-macrofollicular 4
cytic Solid-trabecular 4
nizing
becular
Trabecular 4
mical persistence disease; PD, progression disease.
from the same patient.
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172 :5 575microscope (Olympus, Hamburg, Germany) with appro-
priate fluorescence excitation/emission filters. The signals
were recorded by a CCD camera (Olympus Digital
Camera). For microscopic evaluation, at least 100 intact
and nonoverlapping cell nuclei were scored for the
presence of a split signal. Only cells with two overlapping
signals or one split and one overlapping signal were
counted to ensure only complete cell nuclei had been
scored. The signal pattern interpretation was as follows:
interphase nucleus with two co-localized green/red fusion
signals identified normal chromosomes ten, while a
separated red and green signals and green/red fusion
signals indicated rearranged RET.FISH cut-off level
To establish the cut-off level for RET/PTC rearrangements,
we performed FISH analysis on ten normal thyroid
parenchyma and 100 nuclei were scored for the presence
of a split signal. As previously reported, the cut-off value
was calculated as mean value C3 S.D. of RET rearranged
cells (23, 37, 50, 55). The resulting mean value was 3.6%
with a S.D. of 2.2%, leading to a positivity threshold of
10.2% (3.6G3!2.2). Therefore, a sample was considered
positive if a broken signal was observed in O10.2%
of nuclei.RNA isolation and detection of RET/PTC
rearrangements from frozen neoplastic thyroid tissue
Total RNA was extracted and reverse transcribed into
cDNA. RET/PTC1 and RET/PTC3 rearrangements have
been investigated by qRT-PCR. In a final volume of 20 ml,
we amplified 1 mg cDNA in a mix containing 200 nM final
concentration of specific primers and 100 nM of probes.
Primers forward and probes were as follows:
RET/PTC1, F: 5 0-CGCGACCTGCGCAAA-3 0; RET/PTC3, F:
5 0-CCCCAGGACTGGCTTACCC-3 0; PTC1 probe, 5 0-CAA-
GCGTAACCATCGAGGATCCAAA-3 0; PTC3 probe, 5 0-AAA-
GCAGACCTTGGAGAACAGTCAG-3 0.
For both fragments, primer reverse was: RET/PTC,
R: 5 0-CAAGTTCTTCCGAGGGAATTCC-3 0. To verify the
presence of non-rearranged RET, the following primers
and probe were used: RET, F: 5 0-TGCTTCTGCGAGCCC-3 0,
R: 5 0-ATCACCGTGCGGCACAG-3 0; RET probe 5 0-CATC-
CAGGATCCACTGTGCA-3 0. Thermal cycling profile was
3 min at 95 8C followed by 15 s at 95 8C and 1 min at 60 8C
for 45 cycles. TPC1 cells with RET/PTC1 rearrangement
and NIH3T3 cells with RET/PTC3 rearrangement were usedto form a standard curve composed by five points (from
1000 to 0.1 ng of cDNA with 1:10 dilution) (56).Agarose gel PCR
The generic rearrangement for RET (RET/PTCX) was
analyzed searching for the expression of tyrosine kinase
(TK) and extracellular (EC) domains using the following
primers: EC, F: 5 0-GGCGGCCCAAGTGTGCCGAACTT-3 0,
R: 5 0-CCCAGGCCGCCACACTCCTCACA-3 0; TK, F: 5 0-TG-
GTTCTTGGAAAAACTCTAG-3 0, R: 5 0-CTGCAGGCCCCA-
TACAATTT-3 0. Only samples showing TK expression and
not associated with EC were considered positive for
rearrangement. Thermal cycling conditions included an
initial step (94 8C for 10 min) followed by 35 cycles at
60 8C and a final extension (72 8C for 10 min). TPC1 cells
(rearranged for RET/PTC1) were used as a positive control
and BCPAP cells (carrying the BRAFV600E mutation) were
used as a negative control (42).BRAF status
BRAF sequence was screened for V600E mutation by pyro-
sequencing. DNA was first amplified using ‘RotorGene
6000’ (Corbett Research, St. Neots, Cambridgeshire, UK)
and then sequenced using PyroMark Q96 ID system. PCR
was performed with the following conditions: initial
denaturation at 95 8C for 3 min; 40 cycles at 95 8C for 30 s,
55 8C for 30 s, 72 8C for 30 s; final step 60 8C for 5 min with
TaKaRa Ex Taq (Qiagen). PCR amplification and mutational
analysis were performed in accordance with the Diatech
manual (anti-EGFR MoAb response BRAF status).Statistical analyses
For statistical analysis, the unpaired Student’s t-tests, the
c2, and the Fisher’s exact test were used, as appropriate.
Statistical significance was defined at P!0.05. The P values
were corrected for multiple testing according to Bonfer-
roni. All analyses were performed using GraphPad Prism
version 5.00 for Windows (GraphPad Software, San Diego,
CA, USA; www.graphpad.com).Results
The clinicopathological and molecular features of the
46 PTC (40 PTC BRAF WT and six PTC with BRAFV600E
mutation) and 13 FA cases are given in Tables 1, 2 and 3.
The mean age of the patients with BRAF WT PTC and with
FA was 35.5 and 46.7 years respectively.www.eje-online.org
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Table 3 Clinicopathological features of BRAFWT PTC patients.
One case of FAP-associated papillary carcinoma; one case of
sporadic cribriform-morular variant of papillary carcinoma; one
case of a recurrence nodule in thyroid bed.
Parameter Number
Mean age (years) 35.5 (8–75)
Mean tumor size (mm) 22.5 (3–60)
Diameter %1 cm 13 (32.5%)
Multifocality 12 (33%)
Thyroiditis 16 (44%)
pT1-2 18 (49%)
pT3-4 19 (51%)
pN1 18 (49%)
Stage (AJCC 2009)
I–II 31 (84%)
III–IV 6 (16%)
200 µm
100 µm
100 µm
200 µm
A
C
E
G
B
D
F
H
Figure 2
Histology and corresponding FISH images of representative RET
rearranged PTC samples. (A and B) Classical variant PTC with
predominant follicular growth pattern (case 29, Table 1). Black
arrows indicate papillary structures. (C and D) Classical variant
PTC with a history of exposure to external beam radiotherapy
(case 35, Table 1). (E and F) Solid variant PTC (case 27, Table 1).
(G and H) Diffuse sclerosing variant PTC (case 33, Table 1). White
arrows indicate the rearranged copy of RET. A full colour
version of this figure is available at http://dx.doi.org/10.1530/
EJE-14-0930.
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males, resulting in a female:male ratio of 3.1:1. In the
latter group, there were seven females and five males with
a sex ratio of 1.4:1.
The mean tumor size of the BRAFWT PTC samples was
22.5 mm and 32.5% of them were microcarcinomas.
Moreover, multifocality was present in 33% of the
samples, and lymph node metastases were found in
about 49% of the patients. Following the TNM staging
(57), 31 patients were at stage I and II (Table 3).
Assuming that BRAFV600E mutation and RET/PTC
aberration are usually mutually exclusive (58, 59), the
overall prevalence of RET rearrangement, including all
250 PTCs, was 4% whereas if we consider only the BRAF
WT PTC samples, the prevalence was 25% (10/40 cases)
(Fig. 1).
In detail, eight out of ten RET-positive cases showed a
high percentage of split, ranging from 18 to 50%, while
two cases harbored 12 and 13% of positive nuclei,
respectively (Table 1). In the cases with low percentage
of split, the aberrant cells were found scattered in the
contest of cells harboring normal chromosome 10, with-
out clustering. RET rearrangement was observed in nine
sporadic PTCs (two solid, two classical, three follicular,
two diffuse sclerosing variants) and in one with a history of
exposure to external beam radiotherapy (classical variant;
Fig. 2). Considering only the group of PTCs exposed to
radiation, the frequency of RET rearrangement was 17%
(one out of six cases with 30% of rearranged cells). The
patient had received whole total body radiotherapy for
leukemia 7 years before the diagnosis and removal of
thyroid cancer (Table 1, case 32). Overall, the patients are
young in age, the majority have lymph node metastaseswww.eje-online.orgat the diagnosis and have PTC variants at the histology,
frequently linked to RET genotype (Table 1).
All six PTC samples, carrying BRAFV600E mutation
detected through pyrosequencing, showed a percentage
of RET-positive cells under the cut-off threshold (range
2–8%) (Table 1). Both molecular aberrations were
mutually exclusive.
AUTHOR COPY ONLY
E
u
ro
p
e
a
n
Jo
u
rn
a
l
o
f
E
n
d
o
cr
in
o
lo
g
y
Clinical Study C Colato and others RET activation in papillary
thyroid carcinoma
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are depicted in Table 1.
All ten RET positive PTC cases analyzed by FISH
matched well with qRT-PCR data. In particular, nine out of
ten cases (n. 20b, 24, 26, 27, 28, 29, 30, 31, and 32) showed
detectable RET/PTC1 mRNA, while one case (n. 25)
exhibited RET/PTC3 mRNA.
Controversial data were obtained in five cases showing
a frequency of rearrangement very close to the cut-off
level. Cases 6, 12, and 16, displaying 6, 9, and 10% of
aberrant nuclei, respectively, showed detectable RET/PTC3
or RET/PTC1 mRNA, while samples n.15 and n.19
exhibited no detectable RET/PTC1, RET/PTC3, and tyro-
sine kinase domain mRNA expression and 10% of split
FISH signals.
Moreover, the remaining 25 BRAF WT PTC cases and
all six BRAFV600E cases were negative by both methods.
Finally, we found RET/PTC activation in one spon-
taneous FA (one out of 13 cases, 7.7%), harboring split signals
in 12% of the nuclei, above the cut-off threshold (Table 2).
The comparison between RET rearranged and non
rearranged PTCs is summarized in Table 4. No significant
differences were found concerning the clinicopathological
features, with the exception of the frequency of extra-
thyroidal invasion which was significantly higher in
tumors with RET rearrangement than those harboring
RET WT (PZ0.027; Table 4).Discussion
RET/PTC was the first chimeric gene with oncogenic
potential described in a tumor of epithelial origin andTable 4 Comparison between the clinico-pathological data of
rearranged and non-rearranged RET/PTC samples.
Rearranged
RET
Non-
rearranged
RET P value
Gender (M:F) 1:4 1:2.9 NS
Mean age (yearsGS.E.M.) 31 (G4.1) 37.1 (G3.2) NS
Tumor diameter (mmGS.E.M.) 25.6 (G4.3) 17 (G3.1) NS
Multicentricity 2 (20%) 10 (37%) NS
pT3 9 (90%) 9 (33.3%) 0.027
Thyroiditis 6 (60%) 10 (37%) NS
Lymph node involvement 7 (70%) 11 (40.7%) NS
Stage (AJCC 2009) NS
I–II 9 (90%) 22 (81.5%)
III–IV 1 (10%) 5 (18.5%)
Histological subtype NS
Follicular 3 (30%) 15 (50%)
Classical 3 (30%) 8 (26.7%)
Tall cell 0 (0%) 1 (3.3%)
Others 4 (40%) 6 (20%)represents one of the major genetic alterations found
in PTC (1, 60).
For almost two decades, the pathogenic role of this
hybrid gene both in sporadic PTC (adult and pediatric) and
in PTC developing after ionizing radiation exposure, has
been considered a dogma, but the detection of RET-
positive cells in benign thyroid lesions and the discovery
of heterogeneous distribution of this rearrangement
within an individual nodule have called into question
the belief (22, 24, 25, 37, 61).
Moreover, the clinical significance of RET/PTC
rearrangements is still debated. Indeed, some authors
have suggested that RET rearrangements are associated
with local invasion and distant metastases (17, 26, 62, 63,
64, 65) while other authors associated with early-stage
small PTCs and better prognosis (30, 66, 67, 68, 69, 70).
However, these studies assumed that all types of rearrange-
ment have comparable properties and considered them
as a group (19).
Thus, the current challenge in using RET/PTC analysis
affects the interpretation of dataset results. Finding an
accurate, reliable, and clinically pragmatic strategy for
RET/PTC detection becomes imperative because the
detection of RET/PTC has been offered as a diagnostic
tool for PTC in the surgical and preoperative cytological
material (3, 21, 40, 41, 42, 43, 44). FISH is considered as the
assay of choice for rearrangement detection on formalin-
fixed surgical samples (71) and according to Marotta et al.
(21), at present, it is the most suitable method for
detecting clonal changes. Moreover, the application of
interphase FISH on thyroid tumors is appropriate as
tumors of endocrine glands are known to have a low
growth rate (72).
The aim of this study was to investigate the prevalence
of RET rearrangement by interphase FISH analysis in a
cohort of BRAF WT PTC and to search for a reliable cut-off
value in order to distinguish the occurrence of clonal or
non-clonal RET changes and to explore whether RET/PTC
may be a relevant pathogenic factor.
In our series, we found a total of ten out of 40 (25%)
BRAF WT PTC samples with broken RET above the cut-off
level, a prevalence slightly lower than that reported in
other Italian studies of comparable size, ranging from 27.5
to 35% (16, 30, 62, 73, 74).
This finding could be explained by the significant
decrease in RET/PTC over the years and the equivalent
increasing rate of BRAFV600E and RAS mutations in PTC,
possibly attributed to the decreased exposure to ionizing
radiation in the last decades or to new pollutants (75, 76,
77, 78, 79).www.eje-online.org
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samples in our consecutive series of 250 PTCs is consistent
with Jung et al. (76) who documented the decreasing in
RET/PTC rearrangement from 11 to 2%. This prevalence
was calculated assuming that RET rearrangement and
BRAFV600E mutation are mutually exclusive as reported
in some studies which consider the two genetic alterations
as separated events in PTC without overlap (58, 59).
Moreover, de Biase et al. (80) demonstrated that
BRAFV600E is present in virtually all/the majority neo-
plastic cells in many mutated PTCs supporting the idea of
that this genetic alteration is a founding event, acquired
early during PTC development.
All six BRAFV600E samples tested for RET rearrange-
ments exhibited split signal under the cut-off level.
This finding indirectly confirms the pertinence of the
10.2% threshold for distinguishing non-clonal from sub-
clonal or clonal RET/PTC rearrangement given that
BRAFV600E mutation and RET/PTC aberration are usually
mutually exclusive (58, 59). Moreover, this cut-off level
parallels previous studies, which used a cut-off level of
between 5 and 10% to separate cases from false-positives
(22, 81, 82, 83).
We detected RET/PTC rearrangement in one of the six
patients (17%) with a history of exposure to external beam
radiotherapy. In the context of thyroid irradiation, this
finding is to be considered a low figure, although the
values reported in the literature have been decreasing
recently (71, 75, 84). The high variation of RET/PTC
rearrangements reported in different series can be due to
differences in the prevalence of this alteration in specific
age groups or due to the different time of latency of the
tumors (3, 71, 84, 85).
In order to validate FISH results, we performed
qRT-PCR assay in our study cohort composed of 40 BRAF
WT and six BRAFV600E PTC cases. The FISH results
matched well with qRT-PCR in 41 PTC cases (31 BRAF
WT and six BRAFV600E PTCs), whereas five cases (n. 6, 12,
15, 16, and 19), showing a frequency of rearrangement
very close to the cut-off level, were discordant (Table 1).
This discrepancy may reflect the genetic heterogeneity
within an individual tumor, the different sensitivity of the
detection approaches used in the study and the samples
type used for the comparative analysis, e.g. FFPE material
for FISH analysis and frozen tissue for qRT-PCR, represent-
ing different regions of the same tumor presumably with
different distribution of RET-positive cells (3, 22). More-
over, the documented highly variable levels of RET/PTC
expression in PTC, the identification of which is strictly
dependent on factors that affect the sensitivity, couldwww.eje-online.orgcontribute to explaining the inconsistencies in detection
rates between the DNA-based method (FISH) and RNA-
based assay (qRT-PCR). The existence of quantitative
variation in the expression levels should be taken into
account to investigate the correlation of RET/PTC with
clinical findings (83, 86).
The clinical significance of RET/PTC remains unclear,
with conflicting results between the studies. Considering
the clinicopathological features evaluated in our series,
we found no correlation of RET/PTC expression with age,
gender, tumor size, histological variant, multifocality,
lymphocytic infiltration, and lymph node metastasis, but
the frequency of extrathyroidal invasion in tumors with
RET/PTC expression (9/10, 90%) was significantly higher
than those of RET/PTC negative (9/27, 33%, PZ0.027),
as already reported in three other studies (87, 88, 89).
However, follow-up analysis seems to indicate no influ-
ence of RET expression on patients’ outcome, although
the short follow-up period makes it difficult to draw
definitive and firm conclusions on the prognosis. Accord-
ing to Tallini et al. (68), only one case of PTC with minor
poorly differentiated component (case 23) was negative
for RET rearrangement, confirming the low potential (the
apparent inability) of RET/PTC-positive PTC to progress to
a less differentiated phenotype.
As in the study of Soares et al. (69), our series did
not include papillary microcarcinoma, carrying RET
rearrangement. However, a high prevalence of RET
rearrangement has been detected in papillary microcarci-
nomas by Viglietto et al. (67), leading the authors to
conclude that this genetic alteration is an early event
in PTC tumorigenesis and occurs in tumors with less
propensity to evolve toward clinically more aggressive
forms. Also Corvi et al. (90) found RET activation in 11
microcarcinomas out of 21 (52%) using FISH method. It is
likely that these discrepancies could be attributed to the
different study populations evaluated.
We found RET/PTC activation in one spontaneous FA
(one out of 13 cases, 7.7%), harboring split signals in 12%
of the nuclei. Although, initially, RET rearrangements
were considered as a specific marker for PTC, they have
been sporadically reported in nodules classified as benign
at histology by means of different detection methods
(21, 29, 32, 46). The biological significance of RET/PTC
in benign lesions remains difficult to explain, if we
exclude the occurrence of microfoci of PTC within
an otherwise benign nodule. Some authors have hypo-
thesized that the RET-positive adenomas are composed of
a mixture of cells with and without rearrangement (non-
clonal event), while others suggested that adenomas
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negative (23, 32, 36, 46).
In conclusion, this study demonstrates that inter-
phase break–apart FISH analysis proves a reliable and
sensitive strategy to detect RET/PTC activation in thyroid
tumors, comparable with RT-PCR or Southern blot
analysis with the advantage to allow, on histology
sections, the direct correlation between the histopatholo-
gical features and the distribution of RET rearrangements
in the tumor/nontumor cells. It also represents a powerful
tool to estimate the ratio between broken and non-broken
RET cells in an individual tumor, with the possibility to
separate the clonal (driver mutation) from subclonal event
(passenger mutation) and to quantifying intratumoral
genetic heterogeneity.
Finally, the identification of a precise laboratory FISH
cut-off appears to be a pivotal prerequisite in the
interpretation of the presence of RET rearrangement,
particularly when RET/PTC detection is used for cyto-
logical evaluation of malignancy or for targeted therapy.Declaration of interest
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